# Common Stroke Type Had the Wrong Culprit for Decades > For decades, medicine explained a common type of stroke, lacunar stroke, through a single, well-known cause: the buildup of fatty plaques that - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Commentary - Published: 2026-07-06 - Canonical URL: https://mad-max.co/en/article/l-avc-courant-se-trompait-de-coupable-depuis-des-decennies ## Key takeaways - A study presented at the European Stroke Organisation Conference in May 2026 and published in Circulation found the strongest link to lacunar stroke is ectasia, an abnormal dilation of deep small brain vessels, not narrowing from plaques. - Patients showing this arterial dilation were up to four times more likely to suffer lacunar stroke. - This may partly explain why antiplatelet drugs such as aspirin often work less well for lacunar stroke patients. - The ongoing LACI-3 trial is testing drugs that target the health of small brain vessels, but the findings still need larger, independent validation. - The author stresses that current treatments should not be changed without medical supervision, and that classic risk factors such as high blood pressure, smoking, diabetes and inactivity remain important. ## Introduction: a scientific revision that changes everything ### A decades-old medical dogma called into question For decades, **medicine** explained a common type of **stroke**, **lacunar stroke**, through a single, well-known cause: the buildup of fatty plaques that progressively clog the small **arteries** of the **brain**, a **mechanism** called **atherosclerosis**. This explanation, taught in medical schools worldwide, shaped decades of preventive **treatments** built on this central hypothesis. Yet a **study** presented at the **European Stroke Organisation Conference** in May 2026, and published in the journal **Circulation**, upends this long-established dogma by identifying a radically different **mechanism**, one largely underestimated until now by traditional cardiovascular **research**. ### Why this **discovery** deserves our full attention It's not every day that a piece of **research** challenges such a fundamental pillar of medical understanding for a disease affecting millions of people worldwide every year. **Lacunar stroke**, a common form of **stroke** affecting the deep **small vessels** of the **brain**, may have an origin far more tied to abnormal **dilation** of the **arteries** than to their classic narrowing. This scientific reassessment, if confirmed by larger **studies**, could deeply transform approaches to **prevention** and **treatment** of a condition that too often leaves lasting damage in affected **patients**. *I find it fascinating, and a little dizzying, to see that such an established medical **mechanism** can be called into question this way. It forces me, as a columnist, into real humility about scientific certainties I, like many, believed were set in stone.* ## What this new **study** actually reveals ### **Dilation** of the arteries rather than narrowing Contrary to the dominant hypothesis until now, **researchers** found that the strongest link to **lacunar stroke** does not come from narrowing of the **arteries** by fatty plaques, but rather from a phenomenon called **ectasia**, an abnormal widening or **dilation** of the deep small **blood vessels** of the **brain**. **Patients** showing this arterial **dilation** proved to be up to **four times more likely** to suffer this type of **stroke**. This finding, drawn from data presented at the **European Stroke Organisation Conference** and published in **Circulation**, a scientific journal well regarded in the cardiovascular field, provides a solid enough basis for the international medical community to take it seriously rather than dismiss it as an isolated curiosity. ### Why this technical distinction changes everything The difference between a narrowed vessel and a dilated one might seem purely technical at first glance, but it carries major clinical implications. A vessel blocked by fatty plaques does not respond the same way to **treatments** as a vessel damaged by abnormal **dilation** of its wall, which partly explains why some standard **treatments** have proven disappointing for some **patients** suffering from **lacunar stroke**. This distinction could also explain why classic **prevention**, centered on lowering **cholesterol** and fatty plaques, has never fully solved the problem of recurring **lacunar strokes** in certain **patients** who nonetheless scrupulously follow their **treatment**. *Digging into this topic, I'm struck by how long cardiovascular **medicine** focused on a single **mechanism** without further questioning the cases where classic **treatments** weren't working as expected.* ## Why **aspirin** doesn't always work as expected ### The mystery of ineffective **antiplatelet** treatments This **discovery** could finally explain a clinical mystery that has been frustrating for years: why **antiplatelet** drugs, like **aspirin**, widely prescribed to prevent stroke recurrence, often prove less effective in **patients** with **lacunar stroke** than in those affected by other forms of stroke. If the real cause is not obstruction but vessel **dilation**, the very logic of these treatments becomes questionable for this specific population of **patients**. **Antiplatelet** drugs work by preventing blood clot formation in **arteries** narrowed and weakened by plaques, a mechanism that simply has no equivalent grip on a vessel damaged by structural dilation of its wall. ### Toward a new generation of targeted treatments This reassessment of the underlying mechanism directly feeds into the ongoing **LACI-3** **clinical trial**, which is testing drugs specifically designed to target the health of the brain's **small vessels** rather than relying on a general cardiovascular **prevention** approach. This more targeted approach could eventually offer better outcomes for patients for whom standard treatments regularly fail. It remains essential, however, to remember that this work, while promising, still requires larger-scale validation before it can directly influence official clinical **recommendations** worldwide. *I resist here the temptation to cry miracle, as media coverage of this kind of **discovery** too often does. An ongoing **clinical trial** is a serious lead, not yet a validated treatment ready to change patients' lives tomorrow.* ## What this means concretely for today's patients ### No panic, but renewed vigilance It is crucial to clarify that this **discovery** in no way means current treatments should be abandoned overnight by patients already following an antiplatelet protocol prescribed by their doctor. Any change in treatment must absolutely be made under medical supervision, not based on a popular-science article, however rigorous it may be. What this **research** does change, however, is how doctors might, going forward, guide their **diagnoses** and therapeutic choices when facing a patient showing the characteristic signs of **lacunar stroke**, factoring in the possibility of arterial dilation rather than simple obstruction. ### The importance of **basic research**, often invisible This advance also illustrates, in my view, the crucial importance of patient, methodical **basic research**, far from the media spotlight usually reserved for flashier announcements. It is this kind of foundational work, carried out over several years by rigorous **research** teams, that eventually and quietly transforms medical practice worldwide. Without this kind of methodical questioning of mechanisms otherwise considered settled, **medicine** would remain frozen in certainties that are sometimes outdated, to the detriment of patients who don't respond to standard treatments. *I sincerely believe this story deserves more visibility than the usual sensationalist announcements of a "miracle breakthrough" that too often flood science news and later disappoint the most vulnerable patients.* ## What exactly is a **stroke**, for those outside the field ### Understanding the different types of strokes To fully grasp the importance of this discovery, one must first understand that not all **strokes** are alike. We generally distinguish ischemic **strokes**, caused by an obstruction of blood flow to the **brain**, from hemorrhagic strokes, caused by a ruptured blood vessel. **Lacunar stroke** belongs to the first category, but specifically affects the deep **small vessels** of the **brain**, unlike strokes affecting larger arteries. This form of stroke, though often less dramatic in its immediate **symptoms** than events affecting larger arteries, can nonetheless cause significant **cognitive** and motor damage, particularly when it recurs over time in the same patient. ### Why plain-language science communication matters so much here Clearly explaining these technical distinctions to the general public is not a superfluous exercise: it is necessary so patients understand why their treatment might evolve in the coming years, and why medical research keeps advancing even on subjects thought to be fully understood for a long time. This kind of communication, when done rigorously, also helps defuse unnecessary worry while maintaining healthy vigilance toward **symptoms** that always warrant a prompt medical consultation, whatever their exact cause. *I deeply believe in my role as a translator between complex scientific research and the ordinary reader, without ever sacrificing precision for excessive simplification that would end up distorting the facts.* ## The limits this study cannot yet overcome ### A promising discovery, but not yet definitive It would be dishonest of me to present this study as a definitively established scientific truth. The results presented at the **European Stroke Organisation Conference** and published in **Circulation** constitute a significant advance, but they will need to be confirmed by independent studies conducted on larger, more diverse patient **cohorts** before being considered a new established scientific consensus. Medicine rarely advances through sudden, definitive revolutions: it most often progresses through the cautious accumulation of converging evidence, a process that takes time and demands patience, from **researchers** and from the public following these advances impatiently alike. ### What remains unknown about the precise mechanisms **Researchers** themselves acknowledge they do not yet precisely understand why certain **blood vessels** dilate abnormally in some individuals rather than narrowing through fatty plaque buildup. This question, which touches on fundamental biological mechanisms of vascular aging, remains an active field of research whose definitive answers are still pending. Until these mechanisms are better understood, it would be premature to draw overly hasty conclusions about the exact therapeutic implications of this discovery for all affected patients worldwide. *As a columnist, I prefer to honestly admit the gray areas rather than give in to the temptation to explain everything with a certainty that **science** itself cannot yet afford on this specific subject.* ## The role of clinical trials in validating these discoveries ### How the **LACI-3** trial actually works The ongoing **LACI-3** **clinical trial** specifically tests molecules designed to target the structural health of the brain's small **blood vessels**, rather than relying on a general approach to lowering **cholesterol** or preventing blood clots. This type of trial, conducted over several years with rigorously monitored patient **cohorts**, is the indispensable step before any widespread clinical recommendation. Results from this type of trial, when positive and reproducible, generally take several years to translate concretely into new medical guidelines adopted internationally by the relevant scientific societies. ### Why patience remains necessary for patients For patients living today with a **diagnosis** of **lacunar stroke**, or for their worried loved ones, it is important to understand that the concrete benefits of this discovery, if confirmed, will probably not materialize for several years, the time it takes for clinical research to follow its rigorous and necessary course. This timeline, often frustrating for a public accustomed to instant information, nonetheless remains the essential guarantee that treatments that eventually emerge will be genuinely safe and effective for the patients who receive them. *I understand the legitimate impatience of patients and their families faced with this kind of announcement, but I remain convinced that scientific rigor, even when slow, protects patients better than rushed, poorly grounded hope.* ## What this story says about medicine in general ### **Science** as a permanent process of self-questioning This discovery about **lacunar stroke** perfectly illustrates what genuine scientific inquiry actually is, at its core: a permanent process of self-questioning, never frozen in absolute certainties, even when those certainties have seemed solidly established for decades in reference textbooks. This capacity for self-correction is what fundamentally distinguishes **science** from more dogmatic forms of knowledge. Far from being a sign of weakness, this revision of a widely accepted medical mechanism instead demonstrates the vitality and rigor of an international **scientific community** capable of correcting itself when solid new evidence emerges from within its own ranks. ### Why the general public should follow these developments closely The general public would benefit from following this kind of scientific development more closely, not to hastily change behavior, but to understand that medicine remains a living field, constantly evolving, where yesterday's certainties can be revised tomorrow in light of rigorous new data. This more nuanced understanding of how medical research actually works also helps, in my view, better equip the public against the many false medical claims circulating widely on social media. *I think this story, told well, could help restore confidence in the scientific method itself, at a time when skepticism toward institutional medicine has reached worrying levels in several Western countries.* ## The questions I still ask myself as a columnist ### What I cannot yet claim with certainty As a columnist without medical training, I must honestly admit the limits of my own technical understanding of this research. I cannot, for instance, myself assess the full methodological soundness of the study presented at the **European Stroke Organisation Conference**, nor predict with certainty whether the **LACI-3** trial will confirm the hopes it currently raises within the **scientific community**. What I can do, however, is faithfully relay what the available scientific sources report, while clearly flagging the remaining areas of uncertainty, rather than giving in to the temptation of excessive optimism that would ultimately disserve the patients concerned. ### Why I choose to write about it today anyway I choose to devote this commentary to this discovery precisely because it illustrates, on a small scale, a broader phenomenon: **science's** capacity to reinvent itself in the face of new data, even when that means questioning decades of established clinical practice. It is a story of scientific humility that, in my view, deserves to be told with as much rigor as measured enthusiasm. This story also personally reminds me that intellectual curiosity should never stop, even when facing subjects we believe we fully understand, whether in medicine, geopolitics, or any other complex field I cover in my columns. *I close this commentary with a certain admitted humility: I am not a doctor, but I believe honestly telling this story, with its promises and its limits, serves the reader better than any sensationalist shortcut.* ## What patients and their loved ones can do right now ### Keep following current medical **recommendations** While awaiting the definitive results of the **LACI-3** trial and any further studies, patients diagnosed with **lacunar stroke** or at **risk** must absolutely continue following their treating physician's **recommendations**, without modifying an antiplatelet treatment or any other ongoing therapeutic protocol on their own initiative. This caution is not merely a rhetorical formality: it reflects the reality that current treatments, even imperfect for some patients, remain the best available option given the current state of clinically validated knowledge. ### Stay informed without succumbing to excessive anxiety It is possible, even desirable, to stay informed of these exciting scientific advances without sinking into excessive anxiety over one's own cardiovascular health. The best approach remains open dialogue with one's treating physician, who can put these discoveries into context based on each patient's specific medical profile. This balanced approach, between informed curiosity and clinical caution, seems to me the only responsible way to approach this kind of promising but still-being-validated scientific news. *I'll gladly repeat it: measured hope is always better than panic or rushed euphoria, especially when it comes to the brain health of millions of people worldwide.* ## What this research signals for the future of **neurology** ### A new lead for other cerebrovascular diseases Beyond **lacunar stroke** itself, this discovery about the role of arterial dilation could open interesting research avenues for other cerebrovascular conditions, notably certain forms of **vascular dementia** linked to chronic damage of the brain's **small vessels**, a field where therapeutic options remain particularly limited today. This possibility, still largely speculative at this stage, nonetheless illustrates the importance of continuing to fund patient **basic research** into cerebrovascular mechanisms, a field sometimes less covered by the media than other branches of medical research. ### The measured hope of a more precise medicine If future research confirms the importance of this distinction between arterial narrowing and dilation, medicine could evolve toward a more personalized approach to treating strokes, tailored to the precise mechanism identified in each patient rather than a uniform approach applied indiscriminately to all cases of **lacunar stroke**. This prospect, should it materialize, would represent a significant step toward a more precise, more effective medicine, better able to meet each patient's specific needs based on their actual vascular profile. *Despite all my legitimate methodological reservations, I hold onto measured hope for this research lead. It is exactly this kind of patient advance, far from the spotlight, that sometimes ends up concretely changing lives.* ## The economic and human toll of strokes in our societies ### A **public health** burden often underestimated **Stroke** remains one of the leading causes of acquired disability in adulthood in Western countries, with lasting consequences for mobility, memory and independence among affected patients. **Lacunar stroke**, though often seen as a less dramatic form of **stroke**, contributes significantly to this overall burden, particularly when it recurs silently in the same patient over the years. The human cost of these repeated strokes, often underdiagnosed since their **symptoms** can initially be subtle, translates into a gradual erosion of **cognitive** abilities, a phenomenon affected families unfortunately know all too well without always understanding its precise medical origin. ### Why better understanding the cause improves patient care A better understanding of the actual mechanism behind **lacunar stroke** could, in time, considerably improve care for these patients, more precisely guiding therapeutic choices toward treatments genuinely suited to the identified vascular mechanism rather than a generic approach applied indiscriminately to all patients. This prospect, though still distant in concrete clinical terms, alone justifies continued investment in this kind of **basic research**, whose practical payoffs, when they arrive, durably transform the lives of millions of patients worldwide. *I don't think we talk enough about the real toll of these silent, recurring strokes on the daily lives of patients and their families, a burden that deserves more media visibility than the spectacular announcements alone receive.* ## How to spot the warning signs of a stroke ### The **symptoms** that must never be ignored Regardless of its precise mechanism, every **stroke**, including **lacunar stroke**, shares certain warning symptoms that remain essential to recognize quickly: sudden weakness on one side of the body, sudden speech difficulties, unexpected confusion, or abrupt vision problems. These signs demand immediate medical attention, whatever their exact underlying cause. Speed of care remains, even today, one of the most decisive factors in limiting the long-term damage from a **stroke**, well before the question of the precise mechanism involved in a given patient. ### The role of general **prevention** remains essential Despite this new research lead on arterial dilation, the classic **risk** factors for **stroke**, such as **high blood pressure**, smoking, diabetes and a sedentary lifestyle, remain fully valid and must continue to guide general **prevention** efforts, regardless of the precise mechanism that might be at play in a given patient. This continuity in general prevention messaging is essential to avoid confusion among the public, who might otherwise be tempted to downplay the importance of classic **risk** factors in light of this new scientific discovery. *I want to stress this point: this discovery does not make the usual prevention advice obsolete. It complements it, it does not replace it, and I sometimes worry this kind of nuance gets lost in media simplification.* ## What the international **scientific community** thinks of this ### A cautious but broadly positive reception The first reactions from the international **scientific community** to this discovery presented at the **European Stroke Organisation Conference** appear broadly positive, while retaining the usual methodological caution that characterizes the reception of any new research lead, even one solidly backed by data published in a journal as respected as **Circulation**. This collective caution, far from being a sign of excessive skepticism, simply reflects the rigorous scientific culture that demands independent **replication** before integrating a discovery, however promising, into standard clinical protocols applied internationally. ### The next steps **researchers** are awaiting The researchers involved in this discovery, along with their peers around the world, are now awaiting the results of the **LACI-3** trial and any **replication** studies conducted on larger, more geographically diverse patient **cohorts**, in order to confirm, or potentially qualify, these promising initial results obtained so far. This additional validation stage, though lengthy and sometimes frustrating for an impatient public, remains indispensable to ensure that future clinical **recommendations** rest on sufficiently solid and reproducible scientific foundations. *I actually find it reassuring that the **scientific community** remains cautious about this discovery. It is precisely this collective caution that ultimately protects public trust in evidence-based medicine.* ## Conclusion: a welcome lesson in scientific humility ### What to take away from this discovery This study on **lacunar stroke**, presented at the **European Stroke Organisation Conference** and published in **Circulation**, reminds us that even the most solidly established medical mechanisms can be revised in light of rigorous new evidence. Abnormal dilation of the brain's **small vessels**, rather than their simple narrowing, could explain why some patients do not respond to classic **antiplatelet** treatments. ### Toward a medicine that keeps learning The ongoing **LACI-3** **clinical trial** will determine in the coming years whether this research lead translates into concrete treatments for patients. In the meantime, this story deserves to be told with the rigor it demands: neither rushed sensationalism nor excessive skepticism, but informed curiosity toward a science that, humbly, keeps learning about itself. *I close this commentary with a simple conviction: a science willing to correct itself deserves our trust, not our suspicion. It is precisely this kind of institutional humility that, in the end, saves lives.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - NeuroNews International — Arterial widening identified as potential underlying cause of small vessel disease and lacunar stroke, 2026 - ScienceDaily — Health & Medicine news, accessed July 2026 ### Secondary sources - ScienceDaily — Top Health news, accessed July 2026 - ScienceDaily — Mind & Brain news, accessed July 2026 - News-Medical.net — Neurology condition news - Medical Xpress — Medical research news - EurekAlert — Health news, scientific updates --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/l-avc-courant-se-trompait-de-coupable-depuis-des-decennies